Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases - Top-Institutions - MDSpire

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases

  • By

  • Armelle Otiniano

  • Zoe van de Wyngaert

  • Eolia Brissot

  • Rémy Dulery

  • Joel Gozlan

  • Anne Daguenel

  • Yasmine Abi Aad

  • Laure Ricard

  • Nicolas Stocker

  • Anne Banet

  • Agnes Bonnin

  • Tamim Alsuliman

  • Zora Marjanovic

  • Aurélie Schnuriger

  • Paul Coppo

  • Ollivier Legrand

  • Karine Lacombe

  • Mohamad Mohty

  • Florent Malard

  • December 8, 2022

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Infectious Diseases
    • Immunology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Infectious Diseases

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Infectious Diseases

  • #4

    National Institutes of Health (NIAID)
    National Institutes of Health (NIAID)

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Hematology

  • #5

    Saint Antoine Hospital
    Saint Antoine Hospital

    Paris, France

    Key Differentiators

    • Hematology
    • Infectious Diseases

Original Source(s)

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases

  • by Armelle Otiniano, Zoe van de Wyngaert, Eolia Brissot, Rémy Dulery, Joel Gozlan, Anne Daguenel, Yasmine Abi Aad, Laure Ricard, Nicolas Stocker, Anne Banet, Agnes Bonnin, Tamim Alsuliman, Zora Marjanovic, Aurélie Schnuriger, Paul Coppo, Ollivier Legrand, Karine Lacombe, Mohamad Mohty, Florent Malard

  • December 8, 2022

Related Content

Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis

Severe Parvovirus B19–Associated Myocarditis in Children in the Post–COVID-19 Era: A Multicenter Observational Cohort Study

The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis